Montis Biosciences Employee Directory
Biotechnology ResearchFlanders, Belgium11-50 Employees
Montis Biosciences is a Belgium-based biotechnology company advancing preclinical therapeutics for inflammation-driven autoimmune disorders and neurodegenerative diseases. It relies on a patient-centric discovery platform to develop antibodies with potential to offer new treatment options, including its lead program MB01 which targets C1q to modulate its roles in neuroinflammation and autoimmunity. Unlike prior approaches, its anti-C1q antibodies may affect C1q's complement-independent functions with or without inhibiting the classical complement cascade, potentially altering the treatment landscape in these conditions. The second program, MB02, targets CD93 in lung squamous cell carcinoma, with best-in-class potential in an inflammation-driven oncology indication, and Montis plans to partner this asset. The company is based in Heverlee, in the Flemish region of Belgium, and is in a preclinical stage with plans to initiate two Phase 1 trials in the first half of 2026. In March 2026, the company announced the launch of MB-0109, a new program supported by preclinical data for neuro-autoimmune indications.